718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
2019 ◽
Vol 38
(6)
◽
pp. 1517-1524
◽
2013 ◽
Vol 43
(3)
◽
pp. 305-313
◽
2010 ◽
Vol 9
(9)
◽
pp. 715-734
◽